Not Yet RecruitingNot Applicable

TearCare in Young Adults

United States45 participantsStarted 2026-08-01

Plain-language summary

This study is a non-randomized, open-label, interventional trial of TearCare® eyelid warming and manual meibomian gland expression in young adults with clinically significant meibomian gland dysfunction (MGD). Intervention is with TearCare® performed at Visit 1. A single follow-up examination occurs at Day 28.

Who can participate

Age range18 Years – 29 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years but \<30 years of age
✓. Non-invasive Keratograph break-up time (NIKBUT) \<10 seconds in at least one eye
✓. Meibomian gland secretion score (MGSS) ≤23 for 15 glands in at least one eyelid
✓. OSDI ≥23

Exclusion criteria

✕. Contact lens wear within two weeks of study enrollment or planned during study period
✕. Habitual visual acuity worse than 0.30 logMAR (Snellen equivalent of 20/40) in either eye
✕. Previous or current diagnosis of any autoimmune condition
✕. Use of any of the following medications within 60 days of enrollment:
✕. Topical ophthalmic cyclosporine (including but not limited to Restasis®, Cequa®, Vevye®, generic, or compounded versions)
✕. Xiidra®
✕. Miebo®
✕. Tyrvaya®

What they're measuring

OSDI AT 4 WEEKS

Timeframe: Baseline to 4 weeks

Non-Invasive Keratograph Break-Up Time(NIKBUT) at 4 weeks

Timeframe: Baseline to Week 4

Trial details

NCT IDNCT07579156

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-01

Contact for this trial

Sindhu Gurrala, BDS, MPH

205-975-3881 SOeyes@uab.edu

View on ClinicalTrials.gov More Meibomian Gland Dysfunction (Disorder) trials